» Articles » PMID: 16169853

Elucidation of the Substrate Specificity of the C1s Protease of the Classical Complement Pathway

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2005 Sep 20
PMID 16169853
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the first complement component, the C1 complex, initiates the pathway. In this study we have elucidated the full specificity of the enzyme for the first time using a randomized phage display library. It was found that, aside from the crucial P(1) position, the S(3) and S(2) subsites (in that order) played the greatest role in determining specificity. C1s prefers Leu or Val at P(3) and Gly or Ala residues at P(2). Apart from the S(2)' position, which showed specificity for Leu, prime subsites did not greatly affect specificity. It was evident, however, that together they significantly contributed to the efficiency of cleavage of a peptide. A peptide substrate based on the top sequence obtained in the phage display validated these results and produced the best kinetics of any C1s substrate to date. The results allow an understanding of the active site specificity of the C1s protease for the first time and provide a basis for the development of specific inhibitors aimed at controlling inflammation associated with complement activation in adverse pathological situations.

Citing Articles

The Crystal Structure of the Michaelis-Menten Complex of C1 Esterase Inhibitor and C1s Reveals Novel Insights into Complement Regulation.

Garrigues R, Garrison M, Garcia B J Immunol. 2024; 213(5):718-729.

PMID: 38995166 PMC: 11333171. DOI: 10.4049/jimmunol.2400194.


The axis of complement C1 and nucleolus in antinuclear autoimmunity.

Wu S, Chen J, Teo B, Wee S, Wong M, Cui J Front Immunol. 2023; 14:1196544.

PMID: 37359557 PMC: 10288996. DOI: 10.3389/fimmu.2023.1196544.


Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.

Ikeda Z, Kamei T, Sasaki Y, Reynolds M, Sakai N, Yoshikawa M J Med Chem. 2023; 66(9):6354-6371.

PMID: 37120845 PMC: 10184130. DOI: 10.1021/acs.jmedchem.3c00348.


Quantitative fluorescence resonance energy transfer-based immunoassay for activated complement C1s.

Ye J, Xu J, Zhang C, Zhu L, Xia S Front Immunol. 2023; 14:1081793.

PMID: 36761732 PMC: 9904206. DOI: 10.3389/fimmu.2023.1081793.


Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis.

Radanova M, Vasilev V, Mihaylova G, Kosturkova M, Kishore U, Roumenina L Int J Mol Sci. 2022; 23(16).

PMID: 36012546 PMC: 9409282. DOI: 10.3390/ijms23169281.